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Abstract: Stem cells and cancer have been found to be amazingly closely intertwined with one another in such
a way that they form a meshwork that can help to explain the genesis of cancer and more importantly lead the
way to an effective cure to this dreaded disease. In this study, the link between stem cells and neoplasia is
bridged and novel therapies for cancer are reviewed.
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INTRODUCTION What is an interesting finding is the fact that the
It is interesting that one establishes links between proliferate further. The malignancy of a tumor is due to a
stem cells and cancer and highlight the parallels and limited number of cells which have these stem-like
overlaps between these two fields. properties and which thus confer the ability to cancer
Stem  cells  and  cancer  have  been  found to be cells to divide uncontrollably and colonize secondary
linked  tightly  to  each  other such that at the heart of areas. This finding creates a new paradigm of the
every tumor, some researchers believe, lie a handful of underlying concepts involved in carcinogenesis.
aberrant stem cells that maintain the malignant tissue One can conclude thus, that not all the cells within a
(Wade, 2006). neoplastic growth are equally malignant.  An experiment
In fact, supporting this hypothesis lie a number of conducted in 1961 where cells extracted at random from a
findings which all resulted in the discovery of cancer stem tumor  are  injected  at  a  different site further solidifies
cells in several types of neoplastic growth. this conclusion.  If all the cells extracted had the ability to
Identification of cancer stem cells: The first identification established at the new site.  However, it was reported that
of cancer stem cells by John Dick and his collaborators at if a small sample is used, the probability is that no tumor
the University of Toronto was in certain types of forms. In fact, it requires more than a million cell for a
leukemia. It is quite understandable that stem cells were tumor to be induced at a secondary site. This backs the
first detected in leukemia as opposed to solid tumors concept that the bulk of cells within a tumor are not
since  the  latter  were  impossible  to  distinguish by malignant and only a minor population supports the
means of their surface-protein, a technique which was proliferation of the cancer, indicating the functional
nonetheless established for hematopoietic progenitor heterogeneity of cancer cells. The rest of the cells may be
cells.  However, since the first discovery in 1997, Dr. supportive tissue, acting as a scaffold, providing
Michael Clarke (2003), tracked cancer stem cells in breast mechanical support to the other cells (Department of
tumors.  Cancer cells with stem-like properties have also Health and Human Services, 2005).
been found in human brain tumors in 2004 by Dr. Peter The identification of cancer stem cells in several
Dirks of the University of Toronto and later they have tumors examined may raise certain questions such as Is
been identified in bone cancer by Dr. C. Parker Gibbs of neoplasia the result of aberrant changes in the cell cycle
the University of Florida (Wade, 2006). of the cells making up the organ itself such as brain cells,
In fact, it seems that cancer cells with stem-like for example, or is it the consequence of abnormal
properties reside in every neoplastic growth and this is divisions of the stem cells that reside in that organ?
supported by Dr. Gary Gilliland of Harvard stating that In fact some hypotheses suggest that cancer stem
these types of cells have been reported in every malignant cells  may  arise from a mutation in their DNA and thus
growth examined so far (Wade, 2006). self-renewal fails to be tightly regulated as happens under
majority of cancer cells within a tumor are unable to
proliferate, another neoplastic growth would soon be
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normal conditions.  Moreover, these mutations in the stem cancer stem cells’ population.  The polycomb gene Bmi-1
cell population may have time to accumulate.  Another is crucial for embryogenesis, control of the cell cycle and
possibility is that when a stem cell divides into another lymphopoiesis acting as repressor of transcription of
stem cell and a progenitor cell, the latter, instead of certain genes.  In fact, deletions of this gene in mice leads
differentiating, acquires the property of self-renewal.  All to a gradual loss of hematopoietic lineages because the
in all, cancer stem cells seem to originate from failure of stem cells are unable to self renew (Department of Health
control of the stem cell pool which is usually kept under and Human Services, 2005).
scrutiny (Wade, 2006). In an interesting experiment, genes known to cause
Cancer stem cells derived from a wider spectrum of
tumors throws more light on the role of these stem cells in
the overall pathogenesis of the tumor.   In order to grasp
better the pathogenesis of tumors at all levels, cancer
stem cells derived  from  a wider spectrum of tumors
should be examined as well as focusing on the genetic,
molecular and biochemical mechanisms as well as the
stem-cell niche that all have vital roles in controlling stem
cell renewal and differentiation (Wade, 2006).
IMPLICATIONS OF THE PRESENCE OF
STEM CELLS IN TUMORS
An interesting aspect that emerges from the notion of
cancer stem cells is that assessment of the percentage of
cancer cells that have the potential to initiate the tumor
and thus are responsible for its proliferation may be
related to the rate of spread of the cancer and thus throws
light to its degree of malignancy.  The number of stem
cells responsible for carcinogenesis varies from one type
of cancer to another. For example, in acute myeloid
leukemia only one out of million cells examined had the
ability to maintain proliferation, representing a frequency
of 0.1-1%.  On the other hand, mammary tumor stem cells
make up 2% of the total population while cancer stem cells
in brain may account for 0.3-25% of the tumor cells
(Department of Health and Human Services, 2005).
Conducting these types of experiments in a wider
spectrum of types of cancer can throw more light on the
role of these stem cells in cancer malignancy.
Another promising area to be investigated is that of
delving into the control of these stem cells at the
molecular and genetic level and try to grasp what goes
wrong in the cell cycle of the previously normal stem cells
residing within a particular tissue. What are the intrinsic
and extrinsic factors that trigger stem cells to start
dividing abnormally or cause the progenitor cell to renew
itself instead of differentiating?.
Needless to say, it is crucial to identify the genes and
proteins that govern the processes of self-renewal both in
embryonic and adult stem cells.  
The polycomb gene Bmi-1 and Wnt seem to be vital
for the cell fate and for controlling self renewal and thus
are probable to be involved in supporting and tuning the
leukemia were introduced in mice lacking the polycomb
gene.  Leukemia was indeed induced in these mice but the
cancer was unable to spread to other areas, thus
highlighting the need of this gene for stem cells to be able
to maintain themselves and self-renew (Department of
Health and Human Services, 2005).
The Wnt signal pathway has also been implicated in
hematopoietic malignancy and colon carcinoma and is
believed to be essential for controlling the balance
between self-renewing cells and others that differentiate.
In fact, it is believed to switch off genes in certain cells to
prevent them from self-renewing and thus undergo
differentiation. Mutations in genes involved in this
cascade of events fail to switch off or silence certain
genes, resulting in a continuously transcriptionally-active
state.  This, obviously, disrupts the control of the stem
cell population (Department of Health and Human
Services, 2005).
Hedgehog activity is also implicated in certain lung,
brain, esophagus, skin and other types of cancers.
Experiments have shown that suppressing hedgehog
activity results in killing cancer stem cells which need it
for maintaining the cancer in a proliferative state.  This
means that targeting the pathways involved, by means of
chemotherapeutic drugs, is highly promising although
side effects to other healthy tissues may be inevitable.
Hedgehog together with Wnt are crucial for stem cell
proliferation in circumstances of organ damage and this
may explain how malignancies tend to appear after chronic
irritation to an organ such as alcohol damaging the liver
or chronic acid reflux damaging the epithelium of the
esophagus.
Such experiments that are currently being conducted
and their results raise high hopes for the future of cancer
research and are essential to guide us through a better
understanding of the pathogenesis of cancer at the
molecular and genetic level, with the goal of establishing
much more effective and specific therapies.  In fact, based
on the knowledge that cancer stem cells are responsible
for the proliferation of the tumor, one may target
chemotherapeutic agents specifically to these cells which
are actually the engine of metastasis rather than the entire
bulk of the tumor.  
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The weak point of current chemotherapeutic agents while  the  Pten  gene  is  crucial  for survival  of  the
is that they try to destroy the major part of the cells healthy stem cells, cancer stem cells can endure without
making up the tumor without specifically targeting the this gene (University of Michigan, 2006). 
cancer stem cells which are the main threat and which Needless to say, this is very promising for the
represent a very small minority of the entire tumor.  In fact, demarcation between normal and cancer stem cells and
without being dramatic, one can say that the quest for provides a way of establishing drugs that target
cancer is so close, yet so far away (Stanford University, specifically cancer stem cells.  This goal can be achieved
2004; Wade, 2006). by using drugs that act on the metabolic pathway in
This is highlighted in treatment of chronic which Pten acts.  Cancer and normal stem cells should
myelogenous leukemia using the anticancer drug Gleevac respond  differently  to such a chemical.  The team used
which does not result in complete regression of the the drug rapamycin which suppresses this metabolic
disease.  This may be the result of failure of this drug to pathway and is usually used to transplant rejection.  The
attack specifically cancer stem cells that are ultimately results  showed  that  administration of this drug leads to
responsible  for  cancer proliferation and are the engines a regression  of  leukemic  stem  cells while enhancing
of metastasis (Wade, 2006).  In the account that follows, normal stem cells.  In fact, delivering this drug in mice
promising cancer therapies are discussed, depicted by the immediately after deleting their Pten gene inhibited
use of two main examples, namely chronic myelogenous leukemia to develop whilst those mice that already had
leukemia and breast tumor which is a solid tumor.  Using leukemia lived longer while put on the drug (University of
these types of cancer as an example, helps one to grasp Michigan, 2006).  
the essence that lies in destroying cancer stem cells rather These findings depict the importance of unraveling
than focusing on killing all tumor cells randomly. the  factors  regulating  the  control  of  the normal stem
If this reasoning is viable, a stumbling block is the cell pool so that more specific therapies with less toxic
elimination of these cancer stem cells without killing the side-effects are produced.  However, Morrison underlines
otherwise healthy stem cells.  One way of circumventing the fact that these results are limited to mice and are not
this hurdle may be based on the fact that cancer stem cells yet applied to humans.  More trials need to be conducted
are more energy-consuming than other stem cells and to verify the effectiveness of such drugs in humans as
thus drugs  that  inhibit  normal  cell  processes  and result well.
in a depletion of useful metabolites affect much more Jamieson and her team together with other
cancerous stem cells than normal ones (Wade, 2006). collaborators at Stanford, the University of Toronto,
CANCER STEM CELLS IN CHRONIC responsible for the flourishing of the tumor resembled
MYELOGENOUS LEUKEMIA hematopoietic progenitor cells namely the granulocyte-
Sean J. Morrison from University of Michigan’s cells were derived from the hematopoietic progenitor cells
Center for Stem Cell Biology claims to have conducted in the bone marrow that started renewing themselves
studies that propose means of distinguishing healthy uncontrollably rather than from healthy stem cells
stem cells from cancerous ones (University of Michigan, (Stanford University, 2004).
2006).  In a study in the journal Nature, Morrison’s team A distinguishing characteristic between cancer stem
explained how they not only unraveled distinguishing cells and their progenitors was Beta-catenin, a protein
characteristics of the two types of stem cells but also typically present in embryonic stem cells, conferring their
established drugs that result in different behaviour property of self-renewal.  This protein was also present in
between the two types.  Thus, these differences can be the nucleus of cancer stem cells accounting for their
therapeutically exploited to ensure efficient cancer cure ability to divide uncontrollably. What is interesting is the
(University of Michigan, 2006). fact that many patients who did not respond to the anti-
It  was  found that deletion of the Pten gene from cancer drug Gleevec, possessed large amounts of this
adult  hematopoietic  stem cells in mice induces leukemia protein, thus confirming the relation between this protein
as a result of the production of leukemic stem cells, the and cancer endurance (Stanford University, 2004).
latter  having  the  ability to proliferate and thus are Beta-catenin forms part of a cascade of events
capable of regenerating the tumor at secondary sites. triggered by Wnt protein which, under normal conditions,
Apart  from  enhancing  leukemic  stem  cells, deletion of is active in cells that are continuously dividing such as
the Pten  gene  also  led  to  depletion  of  the  healthy embryonic or stem cells.  Those adult stem cells that do
stem  cell  pool.  The significant  observation was that not  produce Wnt have a limited number of divisions.  The
discovered that the cancer stem cells that were
macrophage progenitors.  This meant that the cancer stem
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team revealed that inhibiting the abnormal activity of
these proteins prevents stem cells from proliferating
uncontrollably.  It follows therefore, that at the root of
several types of cancer lie mutations in proteins
constituting the Wnt pathway.  In fact, mutations in any
protein of the Wnt pathway which result in activation of
the cascade of events are theoretically potent to trigger
neoplastic growth (Stanford University, 2004).
It is only when drugs are produced that inactivate
these proteins that efficient cancer therapy will have legs
to stand on.
Recently,  it  has  also  been  found  that  stem cells
from  bone  marrow  can be used as a vehicle to deliver
anti-tumor  proteins  such as interferon-beta and
interferon-alpha to the site of neoplasia thus providing a Fig. 1a: Cancer stem cells isolated from human breast
means to inhibit progression of chronic myeloid leukemia cancer lost the ability to Arbor (2003)
(Stanford University, 2004).
This is a very promising aspect of oncology that can
lead to suppress cancer proliferation by targeting the cells
responsible for the seedling and colonization of tumor at
secondary sites.
CANCER STEM CELLS IN BREAST TUMOURS
Apart from leukemia, solid tumors were also found to
contain cancer stem cells.  In fact, Michael F.Clarke and
Max S.Wicha together with their collaborators at the
University of Michigan have detected these stem cells in
breast tumors (Touchette, 2003).  Cells from nine human
breast tumors and metastases were examined and the
researchers managed to classify the tumor cells into 2
different categories based on their markers. The Fig. 1 b: Cells from human breast cancer that have spread
distinction became clear when they transplanted these and form tumor (Arbor, 2003)
two types of cells into mice.  The type with the ability to
proliferate  resulted  in carcinogenesis even if small was found to express the protein marker CD44 but had low
number of cells were injected.  This was opposed to the levels, if any, of CD24.  These cells had the ability to seed
cells which lacked the ability to colonize which even when new tumors at secondary sites which had the same
relatively large quantities were used, no tumor developed composition of cells as the original tumor and more
(Touchette, 2003). significantly, were common to all but one of the tumors
A crucial goal is to unravel what renders the cancer they were sampling. The overall consistency of the
stem cells distinct from the rest of the other cells.  This markers in the majority of the tumors is a very promising
can be identified at the genetic level by using DNA lead (Arbor, 2003).
microarrays to detect genes that are only active in cancer Figure 1 (a and b) are images portraying the two main
stem cells and thus are the culprits for the colonizing groups of different cells in a breast tumor and how they
properties of the tumor. stain differently with cell surface markers.
An important milestone towards a better
understanding of cancer stem cells has been their actual CONCLUSION
identification from the other bulk cells forming the tumor.
This was possible by analyzing the cell surface markers Research on cancer stem cells is being conducted at
using specific antibodies and flow cytometry to isolate an extremely great pace.  Science and medicine will have
heterogeneous  cancer  cells.  A particular  group  of  cells championed an important milestone if the stem cells
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responsible for cancer metastasis are understood at the Department of Health and Human Services, 2005. Stem
molecular, biochemical and genetic level.  This knowledge
will be the key to opening doors that lead to effective
chemotherapeutic drugs, targeting to destroy the cells
that ultimately pose the major threat.  Hopefully, if this is
achieved, cancer therapy will no longer be science-fiction
but a concrete aspect of medicine based on molecular and
genetic basis. 
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